Asia Pacific Angina Pectoris drugs Market was worth USD xx billion in 2018 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2023.Angina pectoris refers to the disorder characterised by chest pain due to insufficient blood flow to the heart. It can also be caused due to anaemia, abnormal heart rhythms and heart failure. It Is classified into stable and unstable angina.
Increased prevalence of cardiovascular diseases and rise in the geriatric population are driving the market growth. Increased research and development projects in the healthcare segment and increased healthcare expenditure are further fuelling the market growth. However, the huge investment which goes into developing new drugs is the major factor hampering the growth of the market.
The market for Angina Pectoris drugs is broadly categorized into therapeutic class. By therapeutic class the market is segmented into beta blockers, calcium antagonists, anticoagulants, anti-platelets and others. On the basis of geography, the market is analysed under various regions namely China, India, Japan, Australia and South Korea. Asia Pacific is predicted to grow at a rapid pace in the coming few years.
Some of the major companies dominating the market, by their products and services include Sanofi, Bayer HealthCare, Cardeus Pharmaceuticals and CardioVascular BioTherapeutics (CVBT), Merck & Co. Inc., Anthera Pharmaceuticals, Cardium Therapeutics, Astellas Pharma, Ark Therapeutics Group plc, Torrent Pharmaceuticals Limited, Circ Pharma Limited, HUYA Bioscience International LLC, Lacer S.A., Viromed Co. Ltd. and Baxter Healthcare Corporation.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutic class
5.1.1 Introduction
5.1.2 Beta blockers
5.1.3 Calcium anatagonists
5.1.4 Anticoagulants
5.1.5 Anti platelets
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By therapeutic class
5.1.8 Market Attractiveness Analysis, By therapeutic class
5.1.9 Market Share Analysis, By therapeutic class
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By therapeutic class
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By therapeutic class
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By therapeutic class
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Anthera Pharmaceuticals
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Cardium Therapeutics
8.3 Sanofi
8.4 Bayer HealthCare
8.5 Cardeus Pharmaceuticals
8.6 Ark Therapeutics Group plc
8.7 Torrent Pharmaceuticals Limited
8.8 Circ Pharma Limited
8.9 Viromed Co. Ltd.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
